HAIER BIOMEDICAL(SH:688139) Zheng Quan Ri Bao Zhi Sheng·2026-01-09 13:37Core Viewpoint - The company emphasizes its commitment to investor returns through various methods, including cash dividends, investor relations management, information disclosure, and share buybacks, while focusing on enhancing operational efficiency and profitability through innovation and strategic investments [1] Group 1: Investor Returns - The company has implemented continuous dividends for six years since its listing, with a total dividend payout of 788 million yuan, and the dividend ratio for the 2024 fiscal year has been increased to 40.31% [1] - The actual controller's concerted actors have increased their holdings in the company three times, with a total investment of approximately 384 million yuan [1] - The company has launched three rounds of share buyback plans, with a cumulative buyback amount of about 249 million yuan as of December 31, 2025 [1] Group 2: Share Buyback and Cancellation - To fulfill commitments regarding the buyback plan and enhance investor returns, the company canceled 1,459,586 shares from its buyback on January 6, 2026 [1] Group 3: Business Strategy and Growth - The company focuses on enhancing value creation capabilities through technological innovation, scenario upgrades, and globalization to improve operational efficiency and profitability [1] - It aims to accelerate investment and acquisition processes to strengthen existing industries and expand business boundaries, thereby reshaping its industrial development pattern and enhancing core competitiveness and investment value [1]